Global Hemophilia Gene Therapy Competitive Landscape Professional Research Report 2025

According to DIResearch＇s in-depth investigation and research, the global Hemophilia Gene Therapy market size will reach Million USD in 2025 and is projected to reach Million USD by 2032, with a CAGR of % (2025-2032). Notably, the China Hemophilia Gene Therapy market has changed rapidly in the past few years. By 2025, China＇s market size is expected to be Million USD, representing approximately % of the global market share.

Research Summary

Hemophilia gene therapy is an innovative medical approach aimed at treating hemophilia, a genetic disorder characterized by deficient or dysfunctional blood clotting proteins. Typically, hemophilia gene therapy involves introducing a functional copy of the clotting factor gene into the patient＇s cells, often using viral vectors as delivery vehicles. The goal is to enable the patient＇s cells to produce the missing clotting factor, thereby improving the blood clotting process. This approach holds the potential to provide a more sustained and long-term solution compared to traditional treatments, which often involve regular infusions of clotting factor concentrates. While hemophilia gene therapy is still an evolving field with ongoing research and clinical trials, early results have shown promise in increasing clotting factor levels and reducing the frequency of bleeding episodes in individuals with hemophilia.

The major global suppliers of Hemophilia Gene Therapy include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure, Freeline Therapeutics, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.

This report studies the market size, price trends and future development prospects of Hemophilia Gene Therapy. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Hemophilia Gene Therapy market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Hemophilia Gene Therapy market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Hemophilia Gene Therapy industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.  

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Suppliers of Hemophilia Gene Therapy Include:

Spark Therapeutics

Ultragenyx

Shire PLC

Sangamo Therapeutics

Bioverativ

BioMarin

uniQure

Freeline Therapeutics

Hemophilia Gene Therapy Product Segment Include:

Hemophilia A

Hemophilia B

Hemophilia Gene Therapy Product Application Include:

Female

Male

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global Hemophilia Gene Therapy Industry PESTEL Analysis

Chapter 3: Global Hemophilia Gene Therapy Industry Porter’s Five Forces Analysis

Chapter 4: Global Hemophilia Gene Therapy Major Regional Market Size and Forecast Analysis

Chapter 5: Global Hemophilia Gene Therapy Market Size and Forecast by Type and Application Analysis

Chapter 6: North America Passenger Hemophilia Gene Therapy Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe Hemophilia Gene Therapy Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China Hemophilia Gene Therapy Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) Hemophilia Gene Therapy Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America Hemophilia Gene Therapy Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa Hemophilia Gene Therapy Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global Hemophilia Gene Therapy Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources

Table 1： Global Hemophilia Gene Therapy Market Size Growth Rate by Type, 2024 VS 2025 VS 2032 (US$ Million)

Table 2： Global Hemophilia Gene Therapy Market Size Growth Rate by Application, 2024 VS 2025 VS 2032 (US$ Million)

Table 3： Hemophilia Gene Therapy Industry Development Status

Table 4： Hemophilia Gene Therapy Industry Development Trends

Table 5： Global Hemophilia Gene Therapy Market Size by Region in US$ Million: 2024 VS 2025 VS 2032

Table 6： Global Hemophilia Gene Therapy Revenue by Region (2020-2025) & (US$ Million)

Table 7： Global Hemophilia Gene Therapy Revenue Market Share by Region (2020-2025)

Table 8： Global Hemophilia Gene Therapy Revenue Forecast by Region (2026-2032) & (US$ Million)

Table 9： Global Hemophilia Gene Therapy Revenue Market Share Forecast by Region (2026-2032)

Table 10： Global Hemophilia Gene Therapy Revenue Analysis by Type (2020-2025) & (US$ Million)

Table 11： Global Hemophilia Gene Therapy Revenue Analysis Forecast by Type (2026-2032) & (US$ Million)

Table 12： Global Hemophilia Gene Therapy Revenue Analysis by Application (2020-2025) & (US$ Million)

Table 13： Global Hemophilia Gene Therapy Revenue Analysis Forecast by Application (2026-2032) & (US$ Million)

Table 14： Key Hemophilia Gene Therapy Players in North America

Table 15： North America Hemophilia Gene Therapy Revenue by Type (2020-2025) & (US$ Million)

Table 16： North America Hemophilia Gene Therapy Revenue by Type (2026-2032) & (US$ Million)

Table 17： North America Hemophilia Gene Therapy Revenue by Application (2020-2025) & (US$ Million)

Table 18： North America Hemophilia Gene Therapy Revenue by Application (2026-2032) & (US$ Million)

Table 19： North America Hemophilia Gene Therapy Revenue Market Size by Country (2020-2025) & (US$ Million)

Table 20： North America Hemophilia Gene Therapy Revenue Market Size by Country (2026-2032) & (US$ Million)

Table 21： Key Hemophilia Gene Therapy Players in Europe

Table 22： Europe Hemophilia Gene Therapy Revenue by Type (2020-2025) & (US$ Million)

Table 23： Europe Hemophilia Gene Therapy Revenue by Type (2026-2032) & (US$ Million)

Table 24： Europe Hemophilia Gene Therapy Revenue by Application (2020-2025) & (US$ Million)

Table 25： Europe Hemophilia Gene Therapy Revenue by Application (2026-2032) & (US$ Million)

Table 26： Europe Hemophilia Gene Therapy Revenue Market Size by Country (2020-2025) & (US$ Million)

Table 27： Europe Hemophilia Gene Therapy Revenue Market Size by Country (2026-2032) & (US$ Million)

Table 28： Key Hemophilia Gene Therapy Players in China

Table 29： China Hemophilia Gene Therapy Revenue by Type (2020-2025) & (US$ Million)

Table 30： China Hemophilia Gene Therapy Revenue by Type (2026-2032) & (US$ Million)

Table 31： China Hemophilia Gene Therapy Revenue by Application (2020-2025) & (US$ Million)

Table 32： China Hemophilia Gene Therapy Revenue by Application (2026-2032) & (US$ Million)

Table 33： Key Hemophilia Gene Therapy Players in APAC (excl. China)

Table 34： APAC (excl. China) Hemophilia Gene Therapy Revenue by Type (2020-2025) & (US$ Million)

Table 35： APAC (excl. China) Hemophilia Gene Therapy Revenue by Type (2026-2032) & (US$ Million)

Table 36： APAC (excl. China) Hemophilia Gene Therapy Revenue by Application (2020-2025) & (US$ Million)

Table 37： APAC (excl. China) Hemophilia Gene Therapy Revenue by Application (2026-2032) & (US$ Million)

Table 38： APAC (excl. China) Hemophilia Gene Therapy Revenue Market Size by Country (2020-2025) & (US$ Million)

Table 39： APAC (excl. China) Hemophilia Gene Therapy Revenue Market Size by Country (2026-2032) & (US$ Million)

Table 40： Key Hemophilia Gene Therapy Players in Latin America

Table 41： Latin America Hemophilia Gene Therapy Revenue by Type (2020-2025) & (US$ Million)

Table 42： Latin America Hemophilia Gene Therapy Revenue by Type (2026-2032) & (US$ Million)

Table 43： Latin America Hemophilia Gene Therapy Revenue by Application (2020-2025) & (US$ Million)

Table 44： Latin America Hemophilia Gene Therapy Revenue by Application (2026-2032) & (US$ Million)

Table 45： Latin America Hemophilia Gene Therapy Revenue Market Size by Country (2020-2025) & (US$ Million)

Table 46： Latin America Hemophilia Gene Therapy Revenue Market Size by Country (2026-2032) & (US$ Million)

Table 47： Key Hemophilia Gene Therapy Players in Middle East & Africa

Table 48： Middle East & Africa Hemophilia Gene Therapy Revenue by Type (2020-2025) & (US$ Million)

Table 49： Middle East & Africa Hemophilia Gene Therapy Revenue by Type (2026-2032) & (US$ Million)

Table 50： Middle East & Africa Hemophilia Gene Therapy Revenue by Application (2020-2025) & (US$ Million)

Table 51： Middle East & Africa Hemophilia Gene Therapy Revenue by Application (2026-2032) & (US$ Million)

Table 52： Middle East & Africa Hemophilia Gene Therapy Revenue Market Size by Country (2020-2025) & (US$ Million)

Table 53： Middle East & Africa Hemophilia Gene Therapy Revenue Market Size by Country (2026-2032) & (US$ Million)

Table 54： Global Hemophilia Gene Therapy Market Revenue by Key Suppliers (2021-2025) & (US$ Million)

Table 55： Global Hemophilia Gene Therapy Revenue Market Share by Key Suppliers (2021-2025)

Table 56： Global Key Suppliers Headquarter Location and Key Area Sales

Table 57： Market Mergers & Acquisitions, Expansion

Table 58： Spark Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

Table 59： Spark Therapeutics Hemophilia Gene Therapy Product Portfolio

Table 60： Spark Therapeutics Hemophilia Gene Therapy Revenue (US$ Million), Gross Margin and Market Share (2021-2025)

Table 61： Ultragenyx Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

Table 62： Ultragenyx Hemophilia Gene Therapy Product Portfolio

Table 63： Ultragenyx Hemophilia Gene Therapy Revenue (US$ Million), Gross Margin and Market Share (2021-2025)

Table 64： Shire PLC Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

Table 65： Shire PLC Hemophilia Gene Therapy Product Portfolio

Table 66： Shire PLC Hemophilia Gene Therapy Revenue (US$ Million), Gross Margin and Market Share (2021-2025)

Table 67： Sangamo Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

Table 68： Sangamo Therapeutics Hemophilia Gene Therapy Product Portfolio

Table 69： Sangamo Therapeutics Hemophilia Gene Therapy Revenue (US$ Million), Gross Margin and Market Share (2021-2025)

Table 70： Bioverativ Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

Table 71： Bioverativ Hemophilia Gene Therapy Product Portfolio

Table 72： Bioverativ Hemophilia Gene Therapy Revenue (US$ Million), Gross Margin and Market Share (2021-2025)

Table 73： BioMarin Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

Table 74： BioMarin Hemophilia Gene Therapy Product Portfolio

Table 75： BioMarin Hemophilia Gene Therapy Revenue (US$ Million), Gross Margin and Market Share (2021-2025)

Table 76： uniQure Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

Table 77： uniQure Hemophilia Gene Therapy Product Portfolio

Table 78： uniQure Hemophilia Gene Therapy Revenue (US$ Million), Gross Margin and Market Share (2021-2025)

Table 79： Freeline Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)

Table 80： Freeline Therapeutics Hemophilia Gene Therapy Product Portfolio

Table 81： Freeline Therapeutics Hemophilia Gene Therapy Revenue (US$ Million), Gross Margin and Market Share (2021-2025)

Table 82： Hemophilia Gene Therapy Typical Customer List

Table 83： Hemophilia Gene Therapy Distributors List

Figure 1： Hemophilia Gene Therapy Product Pictures

Figure 2： Hemophilia A Picture Scope

Figure 3： Hemophilia B Picture Scope

Figure 4： Female Picture Scope

Figure 5： Male Picture Scope

Figure 6： Global Hemophilia Gene Therapy Market Size Analysis: 2024 VS 2025 VS 2032 (US$ Million)

Figure 7： Global Hemophilia Gene Therapy Market Revenue and Growth Rate Analysis: (2020-2032) & (US$ Million)

Figure 8： Global Hemophilia Gene Therapy Market Size by Region (2020-2032) & (US$ Million)

Figure 9： Global Hemophilia Gene Therapy Market Share Scenario by Region in Percentage: 2025 Versus 2032

Figure 10： North America Hemophilia Gene Therapy Market Size and Growth Rate (2020-2032) & (US$ Million)

Figure 11： North America Hemophilia Gene Therapy Market Share by Players in 2024

Figure 12： North America Hemophilia Gene Therapy Revenue Market Share by Type (2020-2032)

Figure 13： North America Hemophilia Gene Therapy Revenue Market Share by Application (2020-2032)

Figure 14： US Hemophilia Gene Therapy Revenue (2020-2032) & (US$ Million)

Figure 15： Canada Hemophilia Gene Therapy Revenue (2020-2032) & (US$ Million)

Figure 16： Europe Hemophilia Gene Therapy Market Size and Growth Rate (2020-2032) & (US$ Million)

Figure 17： Europe Hemophilia Gene Therapy Market Share by Players in 2024

Figure 18： Europe Hemophilia Gene Therapy Revenue Market Share by Type (2020-2032)

Figure 19： Europe Hemophilia Gene Therapy Revenue Market Share by Application (2020-2032)

Figure 20： Germany Hemophilia Gene Therapy Revenue (2020-2032) & (US$ Million)

Figure 21： France Hemophilia Gene Therapy Revenue (2020-2032) & (US$ Million)

Figure 22： United Kingdom Hemophilia Gene Therapy Revenue (2020-2032) & (US$ Million)

Figure 23： Italy Hemophilia Gene Therapy Revenue (2020-2032) & (US$ Million)

Figure 24： Spain Hemophilia Gene Therapy Revenue (2020-2032) & (US$ Million)

Figure 25： Benelux Hemophilia Gene Therapy Revenue (2020-2032) & (US$ Million)

Figure 26： China Hemophilia Gene Therapy Market Size and Growth Rate (2020-2032) & (US$ Million)

Figure 27： China Hemophilia Gene Therapy Market Share by Players in 2024

Figure 28： China Hemophilia Gene Therapy Revenue Market Share by Type (2020-2032)

Figure 29： China Hemophilia Gene Therapy Revenue Market Share by Application (2020-2032)

Figure 30： APAC (excl. China) Hemophilia Gene Therapy Market Size and Growth Rate (2020-2032) & (US$ Million)

Figure 31： APAC (excl. China) Hemophilia Gene Therapy Market Share by Players in 2024

Figure 32： APAC (excl. China) Hemophilia Gene Therapy Revenue Market Share by Type (2020-2032)

Figure 33： APAC (excl. China) Hemophilia Gene Therapy Revenue Market Share by Application (2020-2032)

Figure 34： Japan Hemophilia Gene Therapy Revenue (2020-2032) & (US$ Million)

Figure 35： South Korea Hemophilia Gene Therapy Revenue (2020-2032) & (US$ Million)

Figure 36： India Hemophilia Gene Therapy Revenue (2020-2032) & (US$ Million)

Figure 37： Australia Hemophilia Gene Therapy Revenue (2020-2032) & (US$ Million)

Figure 38： Southeast Asia Hemophilia Gene Therapy Revenue (2020-2032) & (US$ Million)

Figure 39： Latin America Hemophilia Gene Therapy Market Size and Growth Rate (2020-2032) & (US$ Million)

Figure 40： Latin America Hemophilia Gene Therapy Market Share by Players in 2024

Figure 41： Latin America Hemophilia Gene Therapy Revenue Market Share by Type (2020-2032)

Figure 42： Latin America Hemophilia Gene Therapy Revenue Market Share by Application (2020-2032)

Figure 43： Mexico Hemophilia Gene Therapy Revenue (2020-2032) & (US$ Million)

Figure 44： Brazil Hemophilia Gene Therapy Revenue (2020-2032) & (US$ Million)

Figure 45： Middle East & Africa Hemophilia Gene Therapy Market Size and Growth Rate (2020-2032) & (US$ Million)

Figure 46： Middle East & Africa Hemophilia Gene Therapy Market Share by Players in 2024

Figure 47： Middle East & Africa Hemophilia Gene Therapy Revenue Market Share by Type (2020-2032)

Figure 48： Middle East & Africa Hemophilia Gene Therapy Revenue Market Share by Application (2020-2032)

Figure 49： Saudi Arabia Hemophilia Gene Therapy Revenue (2020-2032) & (US$ Million)

Figure 50： South Africa Hemophilia Gene Therapy Revenue (2020-2032) & (US$ Million)

Figure 51： Global Hemophilia Gene Therapy Revenue Market Share by Key Suppliers in 2024

Figure 52： Global Hemophilia Gene Therapy Industry Competition Landscape

Figure 53： Hemophilia Gene Therapy Industry Chain Analysis

Figure 54： Bottom-Up and Top-Down Research Methods

Figure 55： Key Interview Objectives

Figure 56： Data Cross Validation